Bruno Degano

Bruno Degano

Auto-generated profile, based on publicly available information

Bruno Degano

University of Grenoble Alpes, INSERM, CHU Grenoble Alpes

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2010 in Circulation
Verified
Journal Article
Closed access
MHMarc Humbert
Marc Humbert
OSOlivier Sitbon
Olivier Sitbon
ACAri Chaouat
Ari Chaouat
MBMichèle Bertocchi
Michèle Bertocchi
GHGilbert Habib
Gilbert Habib
GSGérald Simonneau
Gérald Simonneau
Background— Novel therapies have recently become available for pulmonary arterial hypertension. We conducted a study to characterize mortality in a multicenter prospective cohort of patients diagnosed with idiopathic, familial, or anorexigen-associated pulmonary arterial hypertension in the modern management era. Methods and Results— Between October 2002 and October 2003, 354 consecutive adult patients with idiopathic, familial, or anorexigen-associated pulmonary arterial hypertension (56 incident and 298 prevalent cases) were prospectively enrolled. Patients were followed up for 3 years, and survival rates were analyzed. For incident cases, estimated survival (95% confidence intervals [CIs]) at 1, 2, and 3 years was 85.7% (95% CI, 76.5 to 94.9), 69.6% (95% CI, 57.6 to 81.6), and 54.9% (95% CI, 41.8 to 68.0), respectively. In a combined analysis population (incident patients and prevalent patients diagnosed within 3 years before study entry; n=190), 1-, 2-, and 3-year survival estimates were 82.9% (95% CI, 72.4 to 95.0), 67.1% (95% CI, 57.1 to 78.8), and 58.2% (95% CI, 49.0 to 69.3), respectively. Individual survival analysis identified the following as significantly and positively associated with survival: female gender, New York Heart Association functional class I/II, greater 6-minute walk distance, lower right atrial pressure, and higher cardiac output. Multivariable analysis showed that being female, having a greater 6-minute walk distance, and exhibiting higher cardiac output were jointly significantly associated with improved survival. Conclusions— In the modern management era, idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension remains a progressive, fatal disease. Mortality is most closely associated with male gender, right ventricular hemodynamic function, and exercise limitation.

23 February 2012 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
GSGérald Simonneau
Gérald Simonneau
Adam TorbickiAdam Torbicki
Adam Torbicki
MHMarius Hoeper
Marius Hoeper
MDMarion Delcroix
Marion Delcroix
KKKristóf Karlócai
Kristóf Karlócai
ILIrene M. Lang
Irene M. Lang
In this phase 2 proof-of-concept study we examined the safety and efficacy of selexipag, an orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for pulmonary arterial hypertension (PAH).43 adult patients with symptomatic PAH (receiving stable endothelin receptor antagonist and/or a phosphodiesterase type-5 inhibitor therapy) were randomised three to one to receive either selexipag or placebo. Dosage was up-titrated in 200-μg increments from 200 μg twice daily on day 1 to the maximum tolerated dose by day 35 (maximum allowed dose of 800 μg twice daily). Change in pulmonary vascular resistance at week 17 expressed as a percentage of the baseline value was the primary efficacy end-point, and was analysed in the per protocol set first and then in the all-treated set to assess robustness of results.A statistically significant 30.3% reduction in geometric mean pulmonary vascular resistance was observed after 17 weeks' treatment with selexipag compared with placebo (95% confidence limits -44.7– -12.2; p=0.0045, Wilcoxon rank sum test). This was supported by a similar result from the all-treated set. Selexipag was well tolerated with a safety profile in line with the expected pharmacological effect.Our results encourage the further investigation of selexipag for the treatment of PAH.

1 October 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
ABAthénaïs Boucly
Athénaïs Boucly
LSLaurent SAVALE
Laurent SAVALE
XJXavier Jaïs
Xavier Jaïs
Fabrice BAUERFabrice BAUER
Fabrice BAUER
EBEmmanuel Bergot
Emmanuel Bergot
OSOlivier Sitbon
Olivier Sitbon
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. Methods: A retrospective analysis of incident patients with idiopathic, heritable, or anorexigen-induced PAH enrolled in the French Pulmonary Hypertension Registry (January 2006 to December 2018) was conducted. Survival was assessed according to the initial strategy: monotherapy, dual therapy, or triple-combination therapy (two oral medications and a parenteral prostacyclin). Measurements and Main Results: Among 1,611 enrolled patients, 984 were initiated on monotherapy, 551 were initiated on dual therapy, and 76 were initiated on triple therapy. The triple-combination group was younger and had fewer comorbidities but had a higher mortality risk. The survival rate was higher with the use of triple therapy (91% at 5 yr) as compared with dual therapy or monotherapy (both 61% at 5 yr) (P < 0.001). Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual therapy (10-yr survival, 85% vs. 65%). In high-risk patients (n = 243), the survival rate was higher with triple therapy than with monotherapy or dual therapy, whereas there was no difference between monotherapy and double therapy. In intermediate-risk patients (n = 1,134), survival improved with an increasing number of therapies. In multivariable Cox regression, triple therapy was independently associated with a lower risk of death (hazard ratio, 0.29; 95% confidence interval, 0.11–0.80; P = 0.017). Among the 148 patients initiated on a parenteral prostacyclin, those on triple therapy had a higher survival rate than those on monotherapy or dual therapy. Conclusions: Initial triple-combination therapy that includes parenteral prostacyclin seems to be associated with a higher survival rate in PAH, particularly in the youngest high-risk patients.

2 January 2010 in AIDS
Verified
Journal Article
Closed access
BDBruno Degano
Bruno Degano
MGMathilde Guillaume
Mathilde Guillaume
LSLaurent Savale
Laurent Savale
David MontaniDavid Montani
David Montani
XJXavier Jaïs
Xavier Jaïs
OSOlivier Sitbon
Olivier Sitbon
Objectives: To examine baseline characteristics and outcome, and to determine variables affecting survival in patients with pulmonary arterial hypertension (PAH) associated with HIV infection (PAH-HIV) in the modern era of highly-active antiretroviral therapy (HAART) and specific PAH therapy. Design: Retrospective review of data from PAH-HIV patients without other associated risk factors for PAH, and comparison with previous series. Methods: Data were reviewed for 77 consecutive patients treated at the French Reference Centre for Pulmonary Hypertension between October 2000 and January 2008. Results were expressed as median [1st–3rd quartile] values. Results: At diagnosis of PAH, 81% patients were on HAART, 79% had a CD4+ count more than 200 cells/μl and 49% had undetectable HIV load. New York Heart Association functional class assessment was II (22%), III (69%), and IV (9%). Six-minute walk distance (6MWD) was 375 [288–421] m, and pulmonary vascular resistance was 689 [524–852] dyn s/cm5. All patients received HAART irrespective of HIV disease stage. Specific PAH therapy was started in 50 patients and led to improvements in 6MWD and haemodynamic parameters. In patients who did not receive specific PAH therapy, 6MWD improved but haemodynamics did not change. Overall survival rate was 88% at 1 year and 72% at 3 years. On multivariate analysis, cardiac index more than 2.8 l/min per m2 and CD4+ lymphocyte count more than 200 cells/μl were independent predictors of survival. Conclusion: In patients with PAH-HIV, HAART seems unable to improve haemodynamic parameters. Prognosis in PAH-HIV is mainly related to CD4+ lymphocyte count and cardiac function.

14 November 2013 in European Respiratory Journal
Verified
Journal Article
Closed access
JCJean-Luc Cracowski
Jean-Luc Cracowski
FCFrançois Chabot
François Chabot
JLJosé Labarère
José Labarère
PFPatrice Faure
Patrice Faure
BDBruno Degano
Bruno Degano
MHMarc Humbert
Marc Humbert

17 September 2008 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
BDB. Degano
B. Degano
AYA. Yaïci
A. Yaïci
JPJ. Le Pavec
J. Le Pavec
LSL. Savale
L. Savale
XJX. Jaïs
X. Jaïs
OSO. Sitbon
O. Sitbon
Bosentan has proven 4-month efficacy in patients with HIV-associated pulmonary arterial hypertension (PAH-HIV). Herein, the long-term outcome of unselected PAH-HIV patients treated with first-line bosentan is described.Data for 59 consecutive World Health Organization (WHO) functional class II–IV PAH-HIV patients treated with first-line bosentan between May 2002 and July 2007 were analysed. HIV status, 6-min walk distance and haemodynamics were assessed at baseline, after 4 months and every 6–12 months thereafter.After 4 months, 6-min walk distance increased from 358±98 to 435±89 m and pulmonary vascular resistance decreased from 737±328 to 476±302 dyn·s·cm−5. At the final evaluation (29±15 months), 6-min walk distance remained stable and pulmonary vascular resistance decreased further to 444±356 dyn·s·cm−5. Haemodynamics normalised in 10 patients. At their last evaluation, these 10 patients were in WHO functional class I, with a 6-min walk distance of 532±52 m. Overall survival estimates were 93, 86 and 66% at 1, 2 and 3 yrs, respectively. Bosentan was safe when combined with highly active antiretroviral therapy, with no negative impact on HIV infection control.The present data confirm the long-term benefits of bosentan therapy in HIV-associated pulmonary arterial hypertension patients with improvements in symptoms, 6-min walk distance and haemodynamics, and with favourable overall survival.